BioMimetic shareholder eyes 25%

By Geert De Lombaerde Posted on December 9, 2009 at 7:59 am

Novo A/S, the Danish health care conglomerate that owns 17 percent of Franklin’s BioMimetic Therapeutics (Ticker: BMTI), has filed a trading plan that will let it systematically raise that stake to up to 25 percent.

SEE ALSO: How Novo has been adding to its BMTI holdings

permalink | Comment on this post

Tags: 10b5-1 plans, 5% owners, BioMimetic Therapeutics Inc., biotechnology, insider trades, Novo A/S  

BioMimetic puts a bow on its offering

By Geert De Lombaerde Posted on June 23, 2009 at 10:24 pm

The Franklin-based biotech has raised $17 million from a rights offering. The company (Ticker: BMTI) had enlisted Novo A/S, its largest shareholder, as a backstop but ended up with more demand that it had shares to sell.

permalink | Comment on this post

Tags: BioMimetic Therapeutics Inc., biotechnology, Novo A/S, stock offerings  

BioMimetic extends rights offering

By Geert De Lombaerde Posted on June 11, 2009 at 4:41 pm

The Franklin-based biotech, which is trying to raise $17 million to give it a cash buffer, has extended the deadline of its rights offering by a week. Over in Denmark, the folks at Novo – who have pledged to backstop the offering – are pulling out their checkbook…

permalink | Comment on this post

Tags: 5% owners, BioMimetic Therapeutics Inc., biotechnology, Interwest Partners LP, Novo A/S, stock offerings  

BioMimetic CEO sells block of stock to biggest investor

By Geert De Lombaerde Posted on January 30, 2009 at 7:12 am

Sam Lynch unloads 50,000 shares in part to cover taxes from exercising options last year. As it has been many times over the past few years, Denmark-based Novo A/S was a willing buyer.

permalink | Comment on this post

Tags: 5% owners, BioMimetic Therapeutics Inc., drug development, insider trades, Novo A/S, pharmaceuticals